[1] KESKITALO J E, ZOLK O, FROMM M F, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin[J]. Clin Pharmacol Ther,2009,86(2):197-203. doi:  10.1038/clpt.2009.79
[2] KAJINAMI K, TAKEKOSHI N, BROUSSEAU M E, et al. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management[J]. Atherosclerosis,2004,177(2):219-234. doi:  10.1016/j.atherosclerosis.2004.09.004
[3] HE B X, SHI L, QIU J, et al. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease[J]. J Clin Pharmacol,2014,54(4):462-467. doi:  10.1002/jcph.229
[4] GAO Y, ZHANG L R, FU Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin[J]. Eur J Clin Pharmacol,2008,64(9):877-882. doi:  10.1007/s00228-008-0502-x
[5] WANG D, GUO Y, WRIGHTON S A, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs[J]. Pharmacogenomics J,2011,11(4):274-286. doi:  10.1038/tpj.2010.28
[6] BECKER M L, VISSER L E, VAN SCHAIK R H, et al. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy[J]. Pharmacoepidemiol Drug Saf,2010,19(1):75-81. doi:  10.1002/pds.1866
[7] KAJINAMI K, BROUSSEAU M E, ORDOVAS J M, et al. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia[J]. Am J Cardiol,2004,93(1):104-107. doi:  10.1016/j.amjcard.2003.08.078
[8] ROSALES A, ALVEAR M, CUEVAS A, et al. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia[J]. Clinica Chimica Acta,2012,413(3-4):495-501. doi:  10.1016/j.cca.2011.11.003
[9] KIVISTÖ K T, NIEMI M, SCHAEFFELER E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism[J]. Pharmacogenetics,2004,14(8):523-525. doi:  10.1097/01.fpc.0000114762.78957.a5
[10] PENG C, DING Y, YI X, et al. Polymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population[J]. Clin Ther,2018,40(3):469-477.e2. doi:  10.1016/j.clinthera.2018.02.002
[11] CHO S K, OH E S, PARK K, et al. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers[J]. Pharmacogenetics Genom,2012,22(8):598-605. doi:  10.1097/FPC.0b013e3283544085
[12] STORMO C, BOGSRUD M P, HERMANN M, et al. UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone[J]. Mol Diagn Ther,2013,17(4):233-237. doi:  10.1007/s40291-013-0031-x
[13] BIRMINGHAM B K, BUJAC S R, ELSBY R, et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol,2015,71(3):341-355. doi:  10.1007/s00228-014-1801-z
[14] PASANEN M K, FREDRIKSON H, NEUVONEN P J, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin[J]. Clin Pharmacol Ther,2007,82(6):726-733. doi:  10.1038/sj.clpt.6100220
[15] WANG Y, TIAN Y, LV P, et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people[J]. Die Pharmazie,2017,72(6):365-368.
[16] KAMEYAMA Y, YAMASHITA K, KOBAYASHI K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics,2005,15(7):513-522. doi:  10.1097/01.fpc.0000170913.73780.5f
[17] PETERS B J M, RODIN A S, KLUNGEL O H, et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction[J]. Pharmacogenomics,2010,11(8):1065-1076. doi:  10.2217/pgs.10.81
[18] PRADO Y, SAAVEDRA N, ZAMBRANO T, et al. SLCO1B1 c. 388A>G polymorphism is associated with HDL-C levels in response to atorvastatin in Chilean individuals[J]. Int J Mol Sci,2015,16(9):20609-20619. doi:  10.3390/ijms160920609
[19] GRADHAND U, KIM R B. Pharmacogenomics of mrp transporters (ABCC1-5) and bcrp (ABCG2)[J]. Drug Metab Rev,2008,40(2):317-354. doi:  10.1080/03602530801952617
[20] TSAMANDOURAS N, GUO Y Y, WENDLING T, et al. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population[J]. Pharmacogenetics Genom,2017,27(1):27-38. doi:  10.1097/FPC.0000000000000252
[21] KESKITALO J E, KURKINEN K J, NEUVONEN P J, et al. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin[J]. Clin Pharmacol Ther,2008,84(4):457-461. doi:  10.1038/clpt.2008.25
[22] PODURI A, KHULLAR M, BAHL A, et al. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy[J]. DNA Cell Biol,2010,29(10):629-637. doi:  10.1089/dna.2009.1008
[23] KAJINAMI K, BROUSSEAU M E, ORDOVAS J M, et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner[J]. Am J Cardiol,2004,93(8):1046-1050. doi:  10.1016/j.amjcard.2004.01.014
[24] RODRIGUES A C, REBECCHI I M M, BERTOLAMI M C, et al. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent[J]. Braz J Med Biol Res,2005,38(9):1389-1397. doi:  10.1590/S0100-879X2005000900014
[25] DEGORTER M K, TIRONA R G, SCHWARZ U I, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care[J]. Circ Cardiovasc Genet,2013,6(4):400-408. doi:  10.1161/CIRCGENETICS.113.000099
[26] JOHNSON J M, CASTLE J, GARRETT-ENGELE P, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays[J]. Science,2003,302(5653):2141-2144. doi:  10.1126/science.1090100
[27] MEDINA M W, KRAUSS R M. The role of HMGCR alternative splicing in statin efficacy[J]. Trends Cardiovasc Med,2009,19(5):173-177. doi:  10.1016/j.tcm.2009.10.003
[28] YU C Y, THEUSCH E, LO K, et al. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism[J]. Hum Mol Genet,2014,23(2):319-332. doi:  10.1093/hmg/ddt422
[29] LEDUC V, BOURQUE L, POIRIER J, et al. Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia[J]. Pharmacogenet Genomics,2016,26(1):1-11. doi:  10.1097/FPC.0000000000000178
[30] CUEVAS A, FERNÁNDEZ C, FERRADA L, et al. HMGCR rs17671591 SNP determines lower plasma LDL-C after atorvastatin therapy in Chilean individuals[J]. Basic Clin Pharmacol Toxicol,2016,118(4):292-297. doi:  10.1111/bcpt.12493
[31] PEDRO-BOTET J, SCHAEFER E J, BAKKER-ARKEMA R G, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner[J]. Atherosclerosis,2001,158(1):183-193. doi:  10.1016/S0021-9150(01)00410-5
[32] CERDA A, GENVIGIR F D, WILLRICH M A, et al. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin[J]. Lipids Health Dis,2011,10:206. doi:  10.1186/1476-511X-10-206
[33] DESHMUKH H A, COLHOUN H M, JOHNSON T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)[J]. J Lipid Res,2012,53(5):1000-1011. doi:  10.1194/jlr.P021113
[34] LAGOS J, ZAMBRANO T, ROSALES A, et al. APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects[J]. Int J Mol Sci,2015,16(4):7890-7899.
[35] JIANG X Y, ZHANG Q, CHEN P, et al. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin[J]. J Clin Pharm Ther,2012,37(6):719-723. doi:  10.1111/j.1365-2710.2012.01372.x
[36] KAJINAMI K, BROUSSEAU M E, NARTSUPHA C, et al. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin[J]. J Lipid Res,2004,45(4):653-656. doi:  10.1194/jlr.M300278-JLR200
[37] KAJINAMI K, BROUSSEAU M E, ORDOVAS J M, et al. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin[J]. Atherosclerosis,2004,175(2):287-293. doi:  10.1016/j.atherosclerosis.2004.03.015
[38] GU G L, XU X L, YANG Q Y, et al. Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease[J]. Med Sci Monit,2014,20:2824-2829. doi:  10.12659/MSM.892711
[39] STROES E S, THOMPSON P D, CORSINI A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management[J]. Eur Heart J,2015,36(17):1012-1022. doi:  10.1093/eurheartj/ehv043
[40] BRUCKERT E, HAYEM G, DEJAGER S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study[J]. Cardiovasc Drugs Ther,2005,19(6):403-414. doi:  10.1007/s10557-005-5686-z
[41] DU Y M, WANG S Z, CHEN Z Y, et al. Association of SLCO1B1 polymorphisms and atorvastatin safety and efficacy: a meta-analysis[J]. Curr Pharm Des,2019,24(34):4044-4050. doi:  10.2174/1381612825666181219163534
[42] BRUNHAM L R, LANSBERG P J, ZHANG L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin[J]. Pharmacogenomics J,2012,12(3):233-237. doi:  10.1038/tpj.2010.92
[43] MIROŠEVIĆ SKVRCE N, MACOLIĆ ŠARINIĆ V, ŠIMIĆ I, et al. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case–control study[J]. Pharmacogenomics,2015,16(8):803-815. doi:  10.2217/pgs.15.47
[44] LIU J E, LIU X Y, CHEN S, et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study[J]. Eur J Clin Pharmacol,2017,73(11):1409-1416. doi:  10.1007/s00228-017-2318-z
[45] WILKE R A, MOORE J H, BURMESTER J K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage[J]. Pharmacogenetics Genom,2005,15(6):415-421. doi:  10.1097/01213011-200506000-00007
[46] CHATZIZISIS Y S, KOSKINAS K C, MISIRLI G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment[J]. Drug Saf,2010,33(3):171-187. doi:  10.2165/11319380-000000000-00000
[47] FUKUNAGA K, NAKAGAWA H, ISHIKAWA T, et al. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population[J]. BMC Genet,2016,17(1):79. doi:  10.1186/s12863-016-0390-5